RxDoctor Payments Data

Gregory Stidham, MD

Family Medicine · Fayette, ALNPI 1831183219

Payments from drug & device makers

$1,856in general payments, 2019–2025

Across 112 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$402
  • Novo Nordisk$323
  • AbbVie$319
  • Lilly USA, LLC$163
  • AstraZeneca$144
  • GSK$137
  • plus $368 from 11 others

What the payments were for

  • Food & beverage$1,850100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,856 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$136,956
Medicare patients
427
Services billed
2,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$132,537
JardianceEmpagliflozin87$96,374
OzempicSemaglutide92$95,112
TrulicityDulaglutide73$85,156
FarxigaDapagliflozin Propanediol107$83,639
Tresiba Flextouch U-200Insulin Degludec26$47,238
XareltoRivaroxaban49$36,443
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$31,355
MounjaroTirzepatide26$28,538
LinzessLinaclotide33$23,872
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$21,505
Spiriva RespimatTiotropium Bromide19$18,722
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$16,110
JanuviaSitagliptin Phosphate18$15,299
Repatha SureclickEvolocumab21$13,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Tradjenta$70$136,838135 claims
PfizerEliquis$45$132,537166 claims
Lilly USA, LLCTrulicity, Mounjaro$163$113,69499 claims
Novo NordiskOzempic$323$95,11292 claims
AstraZenecaFarxiga, Breztri Aerosphere$144$92,422119 claims
Johnson & JohnsonXarelto, Invokana$402$48,46664 claims
GSKTrelegy Ellipta$137$31,35541 claims
AbbVieLinzess$319$23,87233 claims
MerckJanuvia$17$15,29918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Fayette

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →